Stock Analiz

Delcath Systems, Inc. DCTH

Medical/Dental Instruments · data as of November 13, 2026

$20.55Market cap $715M
Open the interactive analysis →

Delcath Systems, Inc. (DCTH) is a healthcare company listed in the US with a market value of about $715M. In the twelve months to September 30, 2026 it had revenue of $110M and net income of $7M, a net margin of 6.1%.

Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).

Key numbers: a P/E of 128.4, a price to free cash flow of 35.5, a 5-year average ROIC of -128%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 85% below the current price.

About Delcath Systems

Delcath Systems is listed in the US and classified in medical/dental instruments. Revenue went from $1M in 2014 to $85M in 2025, growth of about 48.9% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 350% over three years (dilution for shareholders). It spends 34% of revenue on research and development.

Score: 2.0 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health5/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)128.4
Forward P/E469.7
P/FCF35.5
P/S6.5
P/B5.4
EV/EBITDA103.2
PEG—
Dividend yield0.00%
FCF yield2.8%
Shareholder yield0.8%
Intrinsic value vs. price−85%

Growth and quality

Revenue growth (1 yr)129.1%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-888.2%
ROIC (5-yr avg.)-127.8%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$110M$85M$37M$2M$3M$4M———$3M$2M
Net income$7M$3M-$26M-$48M-$37M-$26M-$24M-$9M-$19M-$45M-$18M
Free cash flow$20M$21M-$19M-$31M-$25M-$23M-$24M-$24M-$15M-$16M-$14M
EPS (diluted)$0.16$0.07$-0.93$-2.94$-4.12$-3.59$-8.35$-342.83$-0.72$-3250.00$-3707.00
Net margin6.1%3.2%-70.9%-2308.9%-1342.7%-721.5%———-1661.8%-902.2%
ROIC—0.4%-17.8%-146.7%-335.3%-139.6%-85.1%——-2679.2%-138.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $28.60, 39% above the current price; targets range from $25.00 to $36.00; the consensus rating is “Strong buy”; expected EPS is $0.18 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Delcath Systems’s P/E ratio?

About 128.4, based on the last twelve months of diluted earnings per share (forward P/E about 469.7).

Is Delcath Systems stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 85% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Delcath Systems pay a dividend?

Not currently.

Is Delcath Systems a good stock to buy?

We do not give buy or sell advice. Delcath Systems scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.